Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis N Hayashi; N Niikura; N Masuda; S Takashima; R Nakamura; ... Breast Cancer Res Treat/149(1)/pp.277-284, 2015-01
Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer. Fukada I Araki K Kobayashi K Shibayama T Takahashi S Hori... PLoS One/11(9), 2016-9
Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer. H Ohzawa; A Miki; T Teratani; S Shiba; Y Sakuma; W Nishim... Oncology Letters./13(3)/pp.1731-1740, 2017-03
COST-EFFECTIVENESS OF FIRST-LINE S-1 THERAPY FOR METASTATIC BREAST CANCER PATIENTS COMPARED WITH TAXANES: AN ANALYSIS BASED ON THE RANDOMIZED PHASE III SELECT BC TRIAL Shiroiwa T.; Fukuda T.; Shimozuma K.; Mouri M.; Hagiwara ... VALUE IN HEALTH/19(7)/pp.A737-A737, 2016-11
Factors affecting enrolment in randomised controlled trials of Japanese patients with metastatic breast cancer. Hozumi Yasuo; Ohsumi Shozo; Mukai Hirofumi; Takahashi Mas... San Antonio Breast Cancer Symposium/2019-12-10--2019-12-14
An efficacy and safety trial of preoperative chemo-endocrine therapy in luminal b-like (HER2-negative) breast cancer Ryoichi Matsunuma Watanabe Toru; Hozumi Yasuo; Koizumi K ... San Antonio Breast Cancer Symposium/2019-12-10--2019-12-14
Evaluation of oral S-1 as a first-line chemotherapy for metastatic HER2-negative breast cancer: An analysis of two randomized phase III studies (SELECT BC-CONFIRM and SELECT BC) Nishimura Reiki; Mukai Hirofumi; Uemura Yukari; Akabane H... Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)/2019-05-31--2019-06-04
Randomized phase 3 study of anthracycline-containing regimens versus S-1 as first-line treatment for metastatic breast cancer (SELECT BC-CONFIRM)-A combined analysis of two randomized phase 3 studies (SELECT BC-CONFIRM and SELECT BC)- Park Y.; Akabane H.; Watanabe T.; Takahashi M.; Sagara Y.... San Antonio Breast Cancer Symposium/2018-12-04--2018-12-08
A prospective randomized multi-center open-label phase III trial of extending aromatase-inhibitor adjuvant therapy to 10 years - Results from 1697 postmenopausal women in the N-SAS BC 05 trial: Arimidex extended adjuvant randomized study (AERAS) Ohtani S.; Iijima K.; Higaki K.; Sato Y.; Hozumi Yasuo; H... San Antonio Breast Cancer Symposium/2018-12-05--2018-12-08
Randomized phase 3 study of anthracycline-containing regimens versus S-1 as first-line treatment for metastatic breast cancer (SELECT BC-CONFIRM) A combined analysis of two randomized phase 3 studies (SELECT BC-CONFIRM and SELECT BC) Park Y Akabane H Watanabe T Takahashi M Sagara Y Nishimur... San Antonio Breast Cancer Symposium/2018-12-05--2018-12-08